Better Combine Chemotherapy with Radiation for Hodgkin’s Disease? Joachim Yahalom George Canellos REFERENCE: Education Session: Saturday June 3rd, 2006 ASCO Annual Meeting, June 2-6, Atla
Better Combine Chemotherapy with Radiation for Hodgkin’s Disease?
Joachim Yahalom


George Canellos
REFERENCE: Education Session: Saturday June 3rd, 2006 ASCO Annual Meeting, June 2-6, Atlanta
Joachim Yahalom, Memorial Sloan-Kettering Cancer Center, New York
Should patients with low-risk early stage Hodgkin’s disease be treated with combined modality treatment? Or can most of them receive chemotherapy alone, and have radiation only in the relatively unlikely event of recurrent disease? Should transplantation be considered? These issues were debated at the 2006 Annual Meeting of the American Society of Clinical Oncology in Atlanta by George Canellos (Dana-Farber Cancer Institute, Boston) and Joachim Yahalom (Memorial Sloan-Kettering Cancer Center, New York). With equal short-term efficacy using either short courses of ABVD chemotherapy followed by involved-field radiotherapy, or curative doses of ABVD alone, the discussions addressed the long-term risks of second tumors and cardiac morbidity, side effects that occasionally resulted from older regimens including whole-body radiation.
[audio:https://www.audiomedica.com/podcasting/asco/06.07.01_ASCO_podcast.mp3]
Related Episodes

Jefferson DeKloe BSc: Big US Study Confirms Benefit of HPV Vaccination for Boys as Well as Girls
The cancer prevention benefit of vaccination against the human papilloma virus cancer prevent are slowly accruing thanks to European, American and other population-based studies. I’m Peter Goodwin wi

Luis Paz-Ares MD PhD: Longer Survival Among Patients with Extensive Stage Small Cell Lung Cancer Treated with Lurbinectedin Maintenance —ASCO 2025
Luis G Paz-Ares MD PhD discdusses the addition of lurbinectedin as maintenance therapy for extensive stage small cell lung cancer (SCLC)

Frank A Sinicrope MD: Stage 3 Colon Cancer with Deficient Mismatch Repair: Big Gains from Atezolizumab Added to Standard Chemotherapy
An interview with: Frank A Sinicrope, MD, Medical Oncologist, Mayo Clinic, Rochester, Minnesota. CHICAGO —Big gains in survival have been reported among patients with stage three, node-positive colon
